"Accounting for Risk" when valuing a Biotech Company.
Phase I clinical trials have a 15% probability of becoming a marketable product. For those in Phase II, the odds of success rise to 30%, and for Phase III, they climb to 60%. Once clinical trials are complete and the drug enters the final FDA approval phase, it has a 90% chance of success.
These improvements in the odds of success translate directly into stock value.
Derisking products enhances the chance of Partnering deals and potential cash flow from peak sales.
--------------
Graft vs. Host Disease (GvHD)
A conservative value for GvHD alone could be around US$200-US$300m.
This assumes a deal size of US$220m, including US$20m as upfront and another US$25m as near term approval milestone for the paediatric indication.
It is expected the balance to be paid as sales milestones with a portion attributed to approval for the adult indication.
It is assumed,
- A lower upfront to take into account the cost of an adult post approval trial
- High double digit royalties of 25%.
Estimate peak sales of ~US$120m for MSC-100-IV in the US
"Accounting for Risk" when valuing a Biotech Company. Phase I...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |